ArticleCureus2025
Efficacy and Safety of Intravenous Ferric Derisomaltose for Chemotherapy-Induced Anemia: A Single-Center Retrospective Study in Japan.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Three-month follow-up of high-dose intravenous iron monotherapy for cancer-related anemia in an ESA-free oncology setting: a real-world cohort study.International journal of clinical oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Chemotherapy-induced anemia (CIA) is a frequent complication in gynecologic cancers. In this study, we evaluated the effectiveness and safety of ferric derisomaltose (FDI), a high-dose intravenous (IV) iron formulation, for treating patients with CIA. Methods In this retrospective study, we analyzed patients with gynecologic cancers and CIA. A total of 29 patients with hemoglobin (Hb) levels <9.0 g/dL, or who were anticipated to fall below this threshold during chemotherapy, received a single 1,000 mg dose of FDI between 2023 and 2024. As a historical control group, 51 patients treated between 2020 and 2021 who did not receive IV iron were included. The primary outcome was the change in Hb level on day 21. Secondary outcomes included red blood cell (RBC) transfusion rates and the incidence of chemotherapy discontinuation, delay, or dose reduction. Results The baseline Hb levels were 7.6 ± 0.4 g/dL in the FDI group and 7.9 ± 0.4 g/dL in the control group. By day 21, the mean Hb level had increased to 9.4 ± 1.0 g/dL in the FDI group, whereas it declined to 7.4 ± 0.7 g/dL in the control group (p < 0.001). Significantly fewer patients required RBC transfusions in the FDI group than in the control group (two [6.9%] and 17 patients [33.3%], respectively; p = 0.007). Chemotherapy modifications occurred in five patients (17.2%) in the FDI group versus 11 patients (21.6%) in the control group (p = 0.642). Conclusion FDI significantly increased the Hb levels and reduced transfusion requirements in patients with gynecologic cancers and CIA. It was well tolerated and may represent a valuable alternative therapeutic option for managing CIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.